Combinatorial Protocols.
Five priority indications where field parameters tuned to the indication pair with bioregulator cargo synchronized to the cellular state that maximizes uptake. Each row is a distinct method-of-use claim and a separate clinical pathway.
Field tuned to the indication. Bioregulator tuned to the cell.
Layer designations refer to the four-layer model. Field parameters describe the operating envelope for the indication. The bioregulator column lists the Khavinson-lineage short peptides selected for synergistic action with the field protocol.
- IndicationOsteoporotic bone restorationLayersL1 + L2Field parameters75 Hz · 1.5 mT · 30 min dailyBioregulatorVasogenixMechanismWnt/β-catenin and Runx2 induction; vascular bioregulator directs perfusion to remodeling zones.
- IndicationCartilage and osteoarthritisLayersL1 + L4Field parameters15 Hz · 0.8 mT · NIR 810 nm concurrentBioregulatorTelogenixMechanismChondroprotective field with IL-1β suppression; bioregulator restores chondrocyte phenotype.
- IndicationDiabetic wound healingLayersL2 + L3Field parameters7.83 Hz carrier with 50 Hz burstBioregulatorLymphogenix + GonadogenixMechanismFibroblast and keratinocyte migration; angiogenic field coupling; immune bioregulator modulation.
- IndicationPeripheral nerve regenerationLayersL1 + L3Field parameters100 Hz TENS with structured fieldBioregulatorCortigenixMechanismSchwann cell activation; axonal guidance via field gradient; neural bioregulator.
- IndicationSenescent tissue rejuvenationLayersL2 + L3 + L4Field parametersSchumann fundamental + complex; NIR 1064 nmBioregulatorTelogenixMechanismMitohormesis with bioelectric pattern restoration and telomerase induction in pineal axis.
Why pairing matters.
Each modality alone has a structural limit. Together those limits cancel, and the combination is synergy rather than addition — the basis for the method-of-use claims that anchor the discipline.
Pure chemistry. No spatial control.
Bioregulators instruct the cell what to make. They bind a target, activate or inhibit a pathway, and diffuse wherever the bloodstream takes them. They have no way to localize their action to the tissue where it is needed.
- What it doesModulates gene expression at receptive cells.
- MechanismTarget binding; pathway activation or inhibition.
- DistributionSystemic via bloodstream; no spatial targeting.
- Limit — spatialCannot select which tissue takes up the cargo.
- Limit — primingActs on whatever cellular state it finds; cannot precondition.
- Limit — doseHigher concentrations needed to overcome non-primed uptake.
Pure context. No cargo.
Pulsed electromagnetic fields instruct the cell where it is and when to act. They open ion channels, prime the membrane, shift bioelectric pattern, and signal the mitochondria — but the cell still makes whatever its current transcription program directs.
The four-layer model- What it doesTells the cell where it is and primes it to act.
- MechanismIon-channel modulation, membrane priming, mitochondrial signaling.
- DistributionSpatially defined by coil geometry; targets the exposed tissue volume.
- Limit — cargoCannot supply the chemical instruction; runs the existing program.
- Limit — specificityCannot select which gene to express; only conditions readiness.
- Limit — durationEffects decay once the field is removed.
New indications neither modality reaches alone.
Bone non-union is a pulsed-field indication. Senescent cell rejuvenation is approached by bioregulators. Senescence-resistant fracture healing in osteoporotic patients is the combination — and it is a new indication, with its own clinical pathway, its own claim set, and its own market. The same pattern holds for diabetic wound care, peripheral nerve regeneration, articular cartilage restoration, and pineal-axis longevity. Five indications. Five claim sets. One platform.